This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Selinexor
Accession Number
DB11942
Type
Small Molecule
Groups
Approved, Investigational
Description

Selinexor is a first in class selective inhibitor of nuclear transport (SINE) compound. It is currently approved for the treatment of multiple myeloma, a cancer which forms from antibody-producing plasma cells.6,7 This condition is typically treated with high dose bortezomib and dexamethasone chemotherapy followed by autologous stem-cell transplant. Other chemotherapies for multiple myeloma include lenalidomide and dexamethasone, thalidomide, and may include melphalan if the patient is not eligible for transplant.8 Selinexor was approved by the FDA in June 2019. It was granted fast track and orphan designation as well as accelerated approval based on single arm, open label trial data. The Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON) trial is planned to finish in 2020.9

Structure
Thumb
Synonyms
  • Selinexor
External IDs
KPT 330 / KPT-330
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
XpovioTablet, film coated20 mg/1OralKaryopharm Therapeutics Inc.2019-07-10Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
31TZ62FO8F
CAS number
1393477-72-9
Weight
Average: 443.313
Monoisotopic: 443.09292698
Chemical Formula
C17H11F6N7O
InChI Key
DEVSOMFAQLZNKR-RJRFIUFISA-N
InChI
InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1-
IUPAC Name
(2Z)-3-{3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl}-N'-(pyrazin-2-yl)prop-2-enehydrazide
SMILES
FC(F)(F)C1=CC(=CC(=C1)C1=NN(\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F

Pharmacology

Indication

Selinexor is indicated for the treatment of relapsed or refractory multiple myeloma in combination with dexamethasone.Label Patients must have received at least 4 prior therapies and have disease which is refractory to least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody.

Associated Conditions
Pharmacodynamics

Selinexor causes cell cycle arrest and apoptosis in cancer cells.Label

Mechanism of action

Selinexor binds to and inhibits exportin-1 (XPO1).Label XPO1 is a nuclear exporter protein which contains a pocket to which nuclear proteins can bind. When complexed with these proteins and Ran, activated through guanosine triphosphate (GTP) binding, the XPO1-protein-Ran-GTP complex is able to exit the nucleus through a nuclear pore. Once outside, GTP is hydrolyzed and the complex dissociates.4 The inhibition of this process in cancer cells allows the targets of XPO1, many of which are tumor suppressors, to collect in the nucleus and result in increased transcription of tumor suppressor genes. Tumor suppressor proteins known to be affected by XPO1 inhibition include p53, p73, adenomatous polyposis coli, retinoblastoma, forkhead box protein O, breast cancer 1, nucleophosmin, and merlin. Regulators of cell cycle progression are also affected, namely p21, p27, galectin-3, and Tob. Inhibitor of NFκB also collects in the nucleus as a result leading to reduced activity of NFκB, a known contributor to cancer.4,5 XPO1 participates in the formation of a complex with eukaryotic initiation factor 4E and contributes to the transport of messenger RNA for several oncegenes including cell cycle promotors, cyclin D1, cyclin E, and CDK2/4/6, as well as antiapoptotic proteins, Mcl-1 and Bcl-xL.4 These wide ranging changes in protein expression and gene transcription culminate in cell cycle arrest and the promotion of apoptosis in cancer cells.

TargetActionsOrganism
AExportin-1
inhibitor
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

A single 80 mg dose of selinexor produces a mean Cmax of 680 ng/mL and a mean AUC of 5386 ng*h/mL.Label This relationship is dose proportion over the range of 3-85 mg/m2 which encompasses the range of 0.06-1.8 times the approved dosage. The official FDA labeling reports the Tmax as 4 hours but phase 1 studies have found a range of 2-4 hours.Label,1,2,3 Administering selinexor with food, either a high or low fat meal, results in an increase in the AUC of approximately 15-20% but this is not expected to be clinically significant.2

Volume of distribution

The mean apparent volume of distribution is 125L.Label A phase 1 study reported mean apparent volumes of distribution ranging from 1.9-2.9 L/kg in their investigation of food and formulation effects.2

Protein binding

Selinexor is 95% bound to plasma proteins.Label

Metabolism

Selinexor is known to be metabolized through CYP3A4, UDP‐glucuronosyltransferases, and glutathione S-transferases although the metabolite profile has yet to be characterized in published literature.Label The primary metabolites found in urine and plasma are glucuronide conjugates.3

Route of elimination
Not Available
Half life

Selinexor has a mean half-life of elimination of 6-8 hours.Label,1,2,3

Clearance

Selinexor has a mean apparent clearance of 17.9 L/h.Label

Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AmbrisentanThe excretion of Ambrisentan can be decreased when combined with Selinexor.
AtorvastatinThe excretion of Atorvastatin can be decreased when combined with Selinexor.
CaspofunginThe excretion of Caspofungin can be decreased when combined with Selinexor.
CholecystokininThe excretion of Cholecystokinin can be decreased when combined with Selinexor.
Cholic AcidThe excretion of Cholic Acid can be decreased when combined with Selinexor.
CobimetinibThe excretion of Cobimetinib can be decreased when combined with Selinexor.
Conjugated estrogensThe excretion of Conjugated estrogens can be decreased when combined with Selinexor.
DocetaxelThe excretion of Docetaxel can be decreased when combined with Selinexor.
ErythromycinThe excretion of Erythromycin can be decreased when combined with Selinexor.
FluvastatinThe excretion of Fluvastatin can be decreased when combined with Selinexor.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Alexander TB, Lacayo NJ, Choi JK, Ribeiro RC, Pui CH, Rubnitz JE: Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia. J Clin Oncol. 2016 Dec;34(34):4094-4101. doi: 10.1200/JCO.2016.67.5066. Epub 2016 Oct 31. [PubMed:27507877]
  2. Gounder MM, Zer A, Tap WD, Salah S, Dickson MA, Gupta AA, Keohan ML, Loong HH, D'Angelo SP, Baker S, Condy M, Nyquist-Schultz K, Tanner L, Erinjeri JP, Jasmine FH, Friedlander S, Carlson R, Unger TJ, Saint-Martin JR, Rashal T, Ellis J, Kauffman M, Shacham S, Schwartz GK, Abdul Razak AR: Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. J Clin Oncol. 2016 Sep 10;34(26):3166-74. doi: 10.1200/JCO.2016.67.6346. Epub 2016 Jul 25. [PubMed:27458288]
  3. Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, Saint-Martin JR, Carlson R, Landesman Y, McCauley D, Rashal T, Lassen U, Kim R, Stayner LA, Mirza MR, Kauffman M, Shacham S, Mahipal A: First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors. J Clin Oncol. 2016 Dec;34(34):4142-4150. doi: 10.1200/JCO.2015.65.3949. Epub 2016 Oct 31. [PubMed:26926685]
  4. Gandhi UH, Senapedis W, Baloglu E, Unger TJ, Chari A, Vogl D, Cornell RF: Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2018 May;18(5):335-345. doi: 10.1016/j.clml.2018.03.003. Epub 2018 Mar 14. [PubMed:29610030]
  5. Xia Y, Shen S, Verma IM: NF-kappaB, an active player in human cancers. Cancer Immunol Res. 2014 Sep;2(9):823-30. doi: 10.1158/2326-6066.CIR-14-0112. [PubMed:25187272]
  6. Xpovio FDA Announcement [Link]
  7. Cancer.ca: Multiple Myeloma [Link]
  8. BC Cancer Agency: Treatment of Multiple Myeloma [Link]
  9. Clinical Trials: BOSTON Trial [Link]
  10. ChemSpider: Selinexor [Link]
External Links
PubChem Compound
71481097
PubChem Substance
347828269
ChemSpider
32701989
ChEMBL
CHEMBL3545185
Wikipedia
Selinexor
FDA label
Download (588 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentChronic Myelogenous Leukemia (CML) in Blast Crisis / Refractory Acute Lymphoblastic Leukemia (ALL) / Refractory Acute Myelogenous Leukemia (AML) / Refractory Biphenotypic Leukemia / Refractory Mixed Lineage Leukemia / Relapsed Acute Lymphoblastic Leukemia (ALL) / Relapsed Acute Myelogenous Leukemia (AML) / Relapsed Biphenotypic Leukemia / Relapsed Mixed Lineage Leukemia1
1Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemias1
1Active Not RecruitingTreatmentDe Novo Myelodysplastic Syndrome / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Secondary Myelodysplastic Syndromes1
1Active Not RecruitingTreatmentMultiple Myeloma (MM) / Relapsed and/or Refractory Multiple Myeloma1
1Active Not RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
1Active Not RecruitingTreatmentSoft Tissue Sarcoma (STS)1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Mixed Phenotype Acute Leukemia (MPAL) / Myelodysplastic Syndromes (MDS)1
1CompletedTreatmentHaematological Malignancies1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentNeoplasms, Colorectal1
1CompletedTreatmentSarcomas1
1CompletedTreatmentTumors, Solid1
1Not Yet RecruitingTreatmentAlveolar Soft Part Sarcoma (ASPS) / Ewing's Sarcoma (ES) / Liposarcoma / Malignant Peripheral Nerve Sheath Tumour (MPNST) / Sarcomas1
1RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia (Secondary AML, sAML)1
1RecruitingTreatmentAdvanced Cancers / Advanced Malignant Neoplasm / Recurrent Malignant Neoplasm / Refractory Malignant Neoplasm1
1RecruitingTreatmentCancer of the Ovary / Endometrial Cancers1
1RecruitingTreatmentChildhood Central Nervous System Neoplasm / Childhood Lymphoma / Childhood Solid Neoplasm / Malignant Gliomas / Recurrent Brain Neoplasm / Recurrent Childhood Central Nervous System Neoplasm / Recurrent Childhood Glioblastoma / Recurrent Lymphoma / Recurrent Malignant Solid Neoplasm / Refractory Central Nervous System Neoplasm / Refractory Lymphomas / Refractory Malignant Solid Neoplasm / Tumors, Solid / WHO Grade III Glioma1
1RecruitingTreatmentChronic Lymphocytic Leukemia (CLL) - Refractory / Leukemia, Prolymphocytic / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Small Lymphocytic Lymphoma1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentLymphoma, B-Cell1
1RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1RecruitingTreatmentRectal Neoplasms1
1RecruitingTreatmentRecurrent Melanoma1
1RecruitingTreatmentRefractory Multiple Myeloma1
1RecruitingTreatmentTumors, Solid1
1TerminatedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
1, 2Active Not RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Stage IV Pancreatic Cancer1
1, 2Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1, 2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemias1
1, 2RecruitingTreatmentDrug Use / GIST / Maximum Tolerated Dose / Metastatic Adult Soft Tissue Sarcoma / Therapeutic Agent Toxicity1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Extranodal Marginal Zone Lymphoma / Recurrent Follicular Lymphoma / Recurrent Indolent Adult Non-Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Waldenstrom Macroglobulinemia / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Extranodal Marginal Zone Lymphoma / Refractory Follicular Lymphoma / Refractory Mantle Cell Lymphoma / Stage III Non-Hodgkin Lymphoma / Stage IV Non-Hodgkin Lymphoma / Transformed Recurrent Non-Hodgkin Lymphoma1
1, 2RecruitingTreatmentMultiple Myeloma (MM)2
1, 2WithdrawnTreatmentDiabetic Foot Ulcers (DFU)1
1, 2WithdrawnTreatmentMultiple Myeloma (MM)1
1, 2WithdrawnTreatmentRecurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma1
2Active Not RecruitingTreatmentGlioblastomas / Gliomas1
2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Active Not RecruitingTreatmentMyelodysplastic Syndromes1
2CompletedTreatmentAcute Myeloid Leukemia (Relapsed/Refractory)1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentCancer, Breast / Cervical Carcinoma / Endometrial Carcinoma / Ovarian Carcinoma1
2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentNeuroendocrine Carcinomas1
2Not Yet RecruitingTreatmentRelapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)1
2RecruitingTreatmentAdvanced thymic carcinoma / Advanced Thymic Epithelial Tumor1
2RecruitingTreatmentAdvanced thymic carcinoma / Advanced Thymic Epithelial Tumour1
2RecruitingTreatmentMultiple Myeloma in Relapse / Relapse/Refractory Multiple Myeloma1
2RecruitingTreatmentPost Essential Thrombocythemia Myelofibrosis / Post Polycythemia Vera Myelofibrosis / Primary Myelofibrosis1
2RecruitingTreatmentRefractory Multiple Myeloma1
2RecruitingTreatmentUntreated Adult Acute Myeloid Leukemia1
2TerminatedTreatmentCastration Levels of Testosterone / Hormone-Resistant Prostate Cancer / Metastatic Castration-Resistant Prostate Cancer (mCRPC) / Metastatic Prostate Carcinoma in the Soft Tissue / Prostate Carcinoma Metastatic in the Bone / PSA Progression / Stage IV Prostate Adenocarcinoma AJCC v71
2TerminatedTreatmentCutaneous T-Cell Lymphoma (CTCL) / Peripheral T-Cell Lymphoma (PTCL)1
2TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2TerminatedTreatmentProstate Cancer1
2TerminatedTreatmentRecurrent Small Cell Lung Carcinoma1
2TerminatedTreatmentRichter's Transformation1
2TerminatedTreatmentSquamous Cell Carcinoma (SCC)1
2WithdrawnTreatmentMultiple Myeloma (MM)1
2WithdrawnTreatmentMyelodysplastic Syndrome1
2, 3RecruitingTreatmentLiposarcomas, Dedifferentiated1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)1
3RecruitingTreatmentEndometrial Cancers1
Not AvailableNo Longer AvailableNot AvailableMultiple Myeloma (MM)1
Not AvailableRecruitingTreatmentAdvanced / Metastatic / Recurrent / Salivary Gland Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral20 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US9079865No2012-07-262032-07-26Us
US9714226No2012-07-262032-07-26Us
US8999996No2012-09-152032-09-15Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility20mg/mLChemSpider: Selinexor
Predicted Properties
PropertyValueSource
Water Solubility0.00555 mg/mLALOGPS
logP2.85ALOGPS
logP3.07ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)12.18ChemAxon
pKa (Strongest Basic)1.34ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area97.62 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity120 m3·mol-1ChemAxon
Polarizability35.61 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenyl-1,2,4-triazoles. These are organic compounds containing a 1,2,4-triazole substituted by a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Triazoles
Direct Parent
Phenyl-1,2,4-triazoles
Alternative Parents
Trifluoromethylbenzenes / Pyrazines / Imidolactams / Vinylogous amides / Heteroaromatic compounds / Acrylic acids and derivatives / Carboxylic acid hydrazides / Azacyclic compounds / Organonitrogen compounds / Organofluorides
show 4 more
Substituents
Phenyl-1,2,4-triazole / Trifluoromethylbenzene / Monocyclic benzene moiety / Pyrazine / Benzenoid / Imidolactam / Acrylic acid or derivatives / Heteroaromatic compound / Vinylogous amide / Carboxylic acid hydrazide
show 14 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Mediates the nuclear export of cellular proteins (cargos) bearing a leucine-rich nuclear export signal (NES) and of RNAs. In the nucleus, in association with RANBP3, binds cooperatively to the NES on its target protein and to the GTPase RAN in its active GTP-bound form (Ran-GTP). Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. Upon transit of a nuclear export complex into the cytoplasm, disassembling of the complex and hydrolysis of Ran-GTP to Ran-GDP (induced by RANBP1 and RANGAP1, respectively) cause release of the cargo from the export receptor. The directionality of nuclear export is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. Involved in U3 snoRNA transport from Cajal bodies to nucleoli. Binds to late precursor U3 snoRNA bearing a TMG cap.
Specific Function
Nuclear export signal receptor activity
Gene Name
XPO1
Uniprot ID
O14980
Uniprot Name
Exportin-1
Molecular Weight
123384.98 Da

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da

Drug created on October 20, 2016 15:03 / Updated on November 02, 2019 02:51